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Typical Rett syndrome (RTT) is a pediatric disorder caused 
by loss-of-function mutations in the methyl-CpG binding 
protein 2 (MECP2) gene. The demonstrated reversibility 
of RTT-like phenotypes in mice suggests that MECP2 gene 
replacement is a potential therapeutic option in patients. 
We report improvements in survival and phenotypic sever-
ity in Mecp2-null male mice after neonatal intracranial 
delivery of a single-stranded (ss) AAV9/chicken β-actin 
(CBA)-MECP2 vector. Median survival was 16.6 weeks 
for MECP2-treated versus 9.3 weeks for green fluorescent 
 protein (GFP)-treated mice. ssAAV9/CBA-MECP2–treated 
mice also showed significant improvement in the pheno-
type severity score, in locomotor function, and in explor-
atory activity, as well as a normalization of neuronal nuclear 
volume in transduced cells. Wild-type (WT) mice receiving 
neonatal injections of the same ssAAV9/CBA-MECP2 vector 
did not show any significant deficits, suggesting a toler-
ance for modest MeCP2 overexpression. To test a MECP2 
gene replacement approach in a manner more relevant 
for human translation, a self-complementary (sc) adeno-
 associated virus (AAV) vector designed to drive MeCP2 
expression from a fragment of the Mecp2 promoter was 
injected intravenously (IV) into juvenile (4–5 weeks old) 
Mecp2-null mice. While the brain transduction efficiency 
in juvenile mice was low (~2–4% of neurons), modest 
improvements in survival were still observed. These results 
support the concept of MECP2 gene therapy for RTT.
Received 14 March 2012; accepted 23 August 2012; advance online 
publication 25 September 2012. doi:10.1038/mt.2012.200
IntroductIon
Most cases of Rett Syndrome (RTT), traditionally considered a 
neurodevelopmental disorder and mainly affecting girls,1,2 involve 
loss-of-function mutations in the methyl-CpG binding protein 2 
(MECP2) gene. MECP2 is X-linked, and in human males the 
complete absence of functional MeCP2 is normally fatal before, 
or soon after, birth. Due to random X chromosome-inactivation 
females are mosaic at a cellular level for MeCP2 expression, and 
the absence of functional MeCP2 in ~50% of their cells leads to 
the typical RTT phenotype. RTT is characterized by a distinctive 
constellation of clinical features including cognitive and motor 
disabilities.1 Knockout of Mecp2 in mice leads to a comparable 
phenotype.3,4 Currently, there are no direct, curative treatments for 
RTT, and the few interventions with demonstrated clinical efficacy 
are given to alleviate symptoms and improve signs. Understanding 
of the genotype-phenotype pathway remains limited and in the 
absence of a well-characterized set of downstream targets based 
on a known mechanism for MeCP2 action, a therapeutic strategy 
targeting the underlying causes of RTT more directly represents 
an attractive way forward. While there are multiple challenges fac-
ing its application in the clinical arena, gene-replacement therapy 
is a potential future treatment option for RTT patients, as post-
natal activation of Mecp2 in mice has been shown to lead to an 
improved phenotype5–7 thus demonstrating that aspects of the dis-
order may be reversible and potentially preventable if early treat-
ment can be instigated.2,8
MECP2 is expressed widely throughout the body but at par-
ticularly high levels in postmitotic central nervous system (CNS) 
neurons postnatally,9–11 and it has been demonstrated that activa-
tion of Mecp2 only in the brain of mice carrying a targeted gene 
results in restoration of a broadly normal phenotype.7,12 However, 
knockout of Mecp2 in adult mice produces RTT-like phenotypes, 
suggesting a persistent role for MeCP2 in the functioning of adult 
neurons.13 It will thus be necessary for gene therapy approaches 
in RTT both to achieve widespread CNS delivery of a  functional 
copy of MECP2 and to maintain long-term expression of the exog-
enously derived MeCP2 protein.13 Recombinant adeno-associated 
virus (AAV) vectors have been used in research and clinical gene 
delivery studies primarily because they transduce nondividing 
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cells and confer long-term, stable gene expression without associ-
ated inflammation or toxicity.14–16 Many AAV vectors are based 
on the genome of AAV serotype 2 (AAV2), whereas transduction 
of cells in the brain can be enhanced through use of the AAV9 
capsid to package the recombinant construct,17 as AAV9 is known 
to be able to cross the blood–brain barrier. AAV has a 4.7 kb sin-
gle-stranded (ss) DNA genome, and modern recombinant AAV 
vectors from which 4.4 kb of the viral genome has been removed 
can be packaged with a similar-sized piece of foreign DNA. A 
more recent advance in AAV vector technology has been the self-
 complementary (sc) vector, whose genome is comprised of comple-
mentary copies of the DNA insert linked in cis through a mutated 
AAV inverted terminal repeat. scAAV vectors have ten to 100-fold 
higher transduction efficiency than traditional ssAAV vectors,18,19 
facilitating applications designed for global delivery of the virus 
particles, such as via intravenous (IV) or intra- cerebrospinal fluid 
injection. However, a potential drawback of scAAV vectors when 
the gene of interest is large is that the packaging capacity is cut in 
half, to ~2.2 kb of foreign DNA.
In the current study, we asked whether several aspects of the 
measurable phenotype of Mecp2-null mice could be improved by 
AAV2/9-mediated delivery of human MECP2 to Mecp2 knockout 
mice. We found that early or delayed postnatal delivery of a tagged 
MECP2 minigene resulted in an improvement in survival and 
overt RTT-like signs and that widespread overexpression of exog-
enous MeCP2 in cells already expressing a functional endogenous 
allele resulted in no obvious phenotype or overt toxicity effect.
results
neonatal cns injection of AAV9/MECP2 results 
in widespread brain expression of MecP2 at near 
physiological cellular levels
RTT is characterized by the onset of overt signs some months post-
natally rather than at birth and a delayed onset is also observed 
in Mecp2-null mice.3,4 A previous study has shown that postnatal 
activation of a silenced Mecp2 gene can prevent the onset of RTT-
like signs in a mouse model,6 suggesting that the introduction of 
a functional copy of Mecp2 may represent a viable therapeutic 
approach. To test this, we cloned the human MECP2_e1 isoform-
coding sequence carrying a C-terminal Myc tag under the chicken 
β-actin (CBA) promoter into an AAV2 vector backbone and 
produced AAV particles with capsid 9 (AAV2/9; this construct 
henceforth referred to as AAV9/CBA-MECP2; Figure 1a). Direct 
brain injection of this vector bilaterally into male neonatal (P0-2) 
wild-type (WT) and Mecp2-null mice (Figure 1b) resulted in the 
widespread expression of transgenic MeCP2 throughout the CNS 
(Figure 1c). Transduction efficiency varied between brain areas, 
while expression endured throughout the course of the study 
(Figure 1c,d; Supplementary Figure S1). Highest transduction 
efficiencies were observed in hypothalamus (41.5 ± 11.3% of all 
cells) and thalamus (37.2 ± 6.3% of cells) with lowest efficiency seen 
in the striatum (6.8 ± 2.3% of cells). Labeling was predominantly 
observed in NeuN-positive cells suggesting preferential transduc-
tion and/or expression in neuronal populations (Figure 1d). In 
contrast, the proportion of transgene-expressing cells immunon-
egative for NeuN (presumed mostly to represent glia) was modest 
(Figure 1d; range 0.5–6.0% of Myc-labeled nuclei).
Maintaining the normal cellular level of MeCP2 has become 
considered to be crucial for normal function as transgenic over-
expression of Mecp2 has a moderate phenotype in mice7 and 
human chromosome Xq28 duplications involving MECP2 result 
in a pronounced clinical phenotype.20,21 Therefore, to quantify 
the cellular level of exogenously derived MeCP2 and relate this 
to endogenous MeCP2 levels, WT mice were injected postnatally 
(P1) with AAV9/CBA-MECP2 and the resultant expression prod-
uct assessed by quantitative immunofluorescence after 12 weeks. 
Analysis of principal cells within hippocampal area CA3 and 
layer V of primary motor cortex (Figure 1e,f) revealed a 105 ± 
0.4–124 ± 0.1% increase in anti-MeCP2 immunofluorescence in 
transduced (Myc-positive) cells relative to untransduced cells, sug-
gesting that the exogenously derived MeCP2 was being expressed 
at ~1–1.25 times native levels. Distribution analysis of MeCP2 
levels (measured as immunofluorescence intensity) in transduced 
and non-transduced cells from four brains revealed endogenous 
MeCP2 levels to be tightly regulated (narrow peak), whereas levels 
in transduced cells were higher and more variable (Figure 1g).
AAV9-mediated neonatal delivery of MECP2 improves 
the rtt-like phenotype and prolongs life span in 
Mecp2-null mice
To establish whether viral-mediated gene delivery of MECP2 can 
improve and/or prevent development of the RTT-like phenotype, 
Mecp2-null and corresponding WT littermate mice were injected 
intracerebrally at an early postnatal time point (P1/P2) with either 
AAV9/CBA-MECP2 or AAV9/green fluorescent protein (GFP) (as a 
nontherapeutic control) and monitored over a 37-week experimen-
tal period. AAV9/GFP-treated null mice showed markedly reduced 
survival compared with WT mice, as expected for this model3 
(Figure 2a; median survival 9.3 weeks, range 5–19 weeks), whereas 
AAV9/CBA-MECP2–treated null mice showed significantly 
extended survival compared with the AAV9/GFP–treated null mice 
(median survival 16.6 weeks; range 7 to >37 weeks; P < 0.0001, 
Gehan-Breslow-Wilcoxon test). In an AAV9/CBA-MECP2–treated 
WT cohort included to investigate the effect of overexpressing exog-
enously derived MeCP2 in the brain, no mortality was observed. 
Two of 12 AAV9/GFP-treated WT mice died suddenly before the 
end of the study. Weekly monitoring of mice for overt RTT-like 
features using an established observational scoring system6,12,22 was 
carried out to investigate the trajectory of the Mecp2-null phenotype 
(Figure 2b). AAV9/GFP control-injected Mecp2-null mice showed 
the expected phenotype with motor/activity and other deficits 
apparent at 3 weeks and a steep increase in phenotype severity score 
over the subsequent weeks. In contrast AAV9/CBA-MECP2–treated 
null mice exhibited slower progression of the phenotype, the sever-
ity of which reached a peak at around 14 weeks and then decreased 
towards WT values (Supplementary Videos S1–S3). This decrease 
was in part due to sudden death in the most severely phenotypic 
mice, but also in part due to the lower and/or improving phenotype 
score in the longest-lived mice (Supplementary Figure S2a). There 
was no difference in severity score between WT mice injected with 
AAV9/CBA-MECP2 and those injected with AAV9/GFP and scores 
in these two groups did not change significantly over the course of 
the study. It should be noted that the downward trajectory of sever-
ity in the AAV9/GFP control-injected Mecp2-null mice at 12 weeks 
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is largely a result of the death of the most severely affected animals 
reducing the mean severity in the survivors rather than a tendency 
for the phenotype severity to peak and then reduce.
As growth deficits are commonly observed in RTT1 and low 
body weight is a prominent characteristic of Mecp2-null mice, 
growth was also monitored weekly in these mice, but the differ-
ence in body weight between AAV9/GFP control-injected Mecp2-
null mice and AAV9/CBA-MECP2–treated Mecp2-null mice 
was not significant (P > 0.05 repeated-measures analysis of vari-
ance (ANOVA)) despite a trend towards improved growth in the 
AAV9/CBA-MECP2–treated mice.
AAV9-mediated neonatal delivery of MECP2 improves 
motor phenotypes in Mecp2-null mice
Movement-related deficits constitute three of the four main criteria 
for RTT diagnosis1 and represent a major feature of the syndrome 
in patients. Similarly, mobility- and movement-dependent behav-
ior deficits constitute prominent characteristics of Mecp2-null 
mice.3,4 To explore the effect of AAV9/CBA-MECP2 treatment on 
movement-related phenotypes, mice were subjected to analysis of 
their locomotory behavior at 8–9 weeks using a treadmill device 
and by open field test (Figure 3a–e). Mice were challenged to per-
form on a treadmill at two different speeds. Challenged at the lower 
speed (10 cm/second), there was no significant difference between 
AAV9/GFP–treated and AAV9/CBA-MECP2–treated Mecp2-null 
mice in their ability to perform to criteria (4/8 and 10/12 mice, 
respectively, could manage the task; Fisher’s exact test, P = 0.14). 
When challenged using the more demanding, high-speed test 
(25 cm/second), none of the AAV9/GFP-treated Mecp2-null mice 
could perform to criteria whereas 50% of AAV9/CBA-MECP2–
treated Mecp2-null mice were still able to successfully complete 
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Figure 1 Widespread expression of exogenous MecP2 across the brain following neonatal delivery via an AAV2/9 vector. (a) MECP2_e1/Myc 
fusion and GFP (control) constructs were cloned into AAV2 backbones under a CBA promoter. (b) Experimental plan in which male wild-type (WT) 
or Mecp2−/y mice were injected intracranially with AAV9/CBA-MECP2 at P0-2, scored for the progression of RTT-like signs from 3 weeks onwards and 
phenotyped quantitatively at weeks 8–10. (c) Representative micrograph (whole brain, parasagittal section) showing the distribution of Myc-tagged 
MeCP2 expression in a 12-week-old WT mouse following bilateral injection. White dashed arrow indicates approximate injection site. Insets are 
higher power micrographs corresponding to the box in the large image showing proportion of Myc +ve (transduced cells) relative to the NeuN-
immunolabeled cell population. (d) Quantification of transduction efficiency (as a proportion of DAPI-stained nuclei) revealed widespread, mainly 
neuronal, distribution across a range of CNS regions. (e) Micrograph showing transduced and non-transduced cells in hippocampal area CA3 in a 
WT male mouse. At a cellular level, exogenous MeCP2 (revealed by Myc immunoreactivity) was localized to neuronal nuclei with a punctate distribu-
tion characteristic of proteins that colocalize with heterochromatin. (f) Injection of AAV9/MECP2 into WT mice led to augmentation of MeCP2 levels 
(native + transgenic) in transduced cells and enabled quantification of relative transgenic MeCP2 abundance. Blue bars show native MeCP2 levels in 
non-transduced cells and red bars show levels of native + transgenic MeCP2 in transduced cells. Transduced cells exhibited mean levels of anti-MeCP2 
immunofluorescence that were 105–124% higher than mean basal levels in untransduced nuclei. (g) Distribution of MeCP2 level (immunofluores-
cence intensity) in transduced and non-transduced layer of V pyramidal cells (primary motor cortex) from four injected brains. Analysis revealed 
native MeCP2 levels to be tightly regulated (narrow peak) while levels in transduced cells showed a broader and positively shifted distribution. Bars: 
c, top, 1 mm; c, bottom, 100 μm. Error bars show mean ± SEM. AAV, adeno-associated virus; AU, arbitrary unit; CBA, chicken β-actin; CNS, central 
nervous system; DAPI, 4′,6-diamidino-2-phenylindole; GFP, green fluorescent protein; ITR, inverted terminal repeat; NeuN, “neuronal nuclei” antigen 
(Rbfox3); polyA, SV40 polyadenylation signal; RTT, Rett syndrome.
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(0/8 versus 6/12 mice, respectively; Fisher’s exact test, P = 0.024). 
All WT mice (both AAV9/CBA-MECP2 and AAV9/GFP treat-
ment groups) could perform at both speeds.
AAV9/GFP-treated Mecp2-null mice (n = 6) showed a sig-
nificant deficit in locomotion-related parameters in the open 
field tests, including movement duration, total distance moved, 
and mean velocity, compared with AAV9/GFP–treated WT 
controls (Figure 3b–d; n = 9; all P < 0.01). In contrast, AAV9/
CBA-MECP2–treated Mecp2-null mice (n = 11) were not signifi-
cantly different from AAV9/GFP-treated WT controls (n = 9), 
while post hoc comparisons revealed significantly higher mean 
velocity and total distance moved parameters in the AAV9/CBA-
MECP2–treated Mecp2-null mice than in the AAV9/GFP-treated 
Mecp2-null cohort (both P < 0.05). AAV9/CBA-MECP2–treated 
WT mice (n = 12) demonstrated performance comparable to that 
of AAV9/GFP-treated WT mice (n = 9; P > 0.05). In addition to 
ambulatory movement, we tested exploration-related behavior by 
assessing rearing frequency in the open field. AAV9/GFP-treated 
Mecp2-null mice showed a significantly reduced rearing frequency 
compared with AAV9/GFP-treated WT mice (P < 0.01), while 
AAV9/CBA-MECP2–treated Mecp2-null mice showed increased 
rearing frequency relative to AAV9/GFP-treated Mecp2-null mice 
(P < 0.05). As with ambulatory movements, there was no differ-
ence between the WT treatment groups.
overt respiratory phenotypes persist following  
AAV9-mediated neonatal delivery of MECP2 to 
Mecp2-null mice
Apneas and abnormal breathing patterns were investigated using 
whole-body plethysmography. At 9 weeks following neonatal 
delivery of AAV9/CBA-MECP2 or AAV9/GFP, Mecp2-null mice 
displayed a characteristic erratic breathing pattern with frequent 
apneas (Figure 3f,g), in contrast to the regular baseline breath-
ing pattern seen in both WT treatment groups. Overall, there was 
no difference in baseline respiratory frequency between geno-
types or treatments (Figure 3h; two-way ANOVA, P > 0.05). An 
increased incidence of apneas (Figure 3g) was observed in the 
Mecp2-null mice compared with the WT mice (two-way ANOVA, 
genotype main effect P < 0.05), but the AAV9/CBA-MECP2– and 
AAV9/GFP-treated mice did not differ. Similarly, higher breath-
ing frequency variability (coefficient of variation%; Figure 3i) was 
observed in the Mecp2-null mice compared with the WT mice, 
but again the AAV9/CBA-MECP2– and AAV9/GFP–treated mice 
did not differ (two-way ANOVA, genotype main effect P < 0.05, 
treatment main effect P > 0.05, n = 7–12 mice per group).
AAV9-mediated delivery of MECP2 rescues the  
Mecp2-null nuclear volume phenotype
A consistent feature of MeCP2 deficiency at the cellular level is a 
reduction in nucleus volume.5,23 In order to assess potential changes 
in this parameter, 3D nuclear volume measures were obtained 
for AAV9/CBA-MECP2–transduced and non- transduced gran-
ule cells of the dentate gyrus (Figure 4). Consistent with previ-
ous reports, non-transduced neurons in Mecp2-null mice showed 
nuclear volumes that were on average 69% of volumes in age-
matched WT mice (Figure 4d). In Mecp2-null mice, AAV9/CBA-
MECP2–transduced cells displayed nuclear volumes that were 
Figure 2 enhanced survival and reduced rtt-like signs following 
neonatal delivery of ssAAV9/cBA-MECP2. (a) Survival plot showing 
extended lifespan of Mecp2−/y mice injected with AAV9/CBA-MEPC2 
(open circles, n = 14) compared with AAV9/GFP-injected controls (open 
squares, n = 11). The median survival period was significantly increased 
from 9.3 to 16.6 weeks (P < 0.0001, Gehan-Breslow-Wilcoxon test). 
The plot also shows absence of lethality associated with overexpres-
sion of MeCP2 in AAV9/MECP2-treated wild-type mice (closed circles, 
n = 12). Closed squares show data from AAV9/GFP-treated wild-type 
mice (n = 12). (b) Plot showing aggregate phenotype severity score in 
the mice used for survival analysis in a. The rate of phenotype progres-
sion in AAV9/MECP2-treated null mice was reduced compared with the 
aggressive phenotype trajectory seen in AAV9/GFP control-injected mice 
(P < 0.05, repeated measures ANOVA between weeks 3–12). In contrast, 
wild-type mice injected with AAV9/MECP2 and AAV9/GFP showed no dif-
ference between groups and no change in score over the study. (c) Plot 
showing body weight changes over time in the same mice. There was a 
genotype effect (repeated-measures ANOVA, P < 0.05) but no significant 
treatment effect. Video camera symbols indicate time points at which 
movies were made (see Supplementary Videos S1–S3). #Indicates 
two AAV9/MECP2-treated Mecp2-null mice that survived to the end of 
the 30-week study (see Supplementary Figure S2). Danger symbol 
indicates that in the null untreated group, insufficient mice were still 
alive to plot the mean score after 12 weeks. AAV, adeno-associated virus; 
ANOVA, analysis of variance; CBA, chicken β-actin; GFP, green fluores-
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significantly larger (by 29% on average) than those of neighbor-
ing non-transduced cells in the same brains, and the AAV9/CBA-
MECP2–transduced cells showed no significant difference from 
values observed in non-transduced WT mice. Interestingly, in 
WT mice, AAV9/CBA-MECP2–transduced cells showed a modest 
(~1.2-fold on average) but significant increase in nuclear volume 
relative to neighboring non-transduced cells (Figure 4c).
IV delivery of MECP2 to the brains of juvenile mice 
using scAAV vectors is less efficient and of more 
limited benefit
Since widespread MECP2 gene delivery is likely to be a prerequisite 
for any successful RTT gene therapy approach, future translational 
studies of AAV-based therapeutic strategies will depend on the 
development of an appropriate scAAV/MECP2 vector. The MECP2 
coding sequence spans nearly 1.5 kb, so packaging this gene in a 
sc form requires the use of a promoter and polyadenylation sig-
nal totaling ≤0.7 kb. A 229 bp truncated portion of the originally 
described 731 bp murine Mecp2 promoter containing the core 
transcriptional control elements was recently described as broadly 
recapitulating the overall pattern of MeCP2 expression.24 Within the 
CNS, this promoter drives expression predominantly in neurons. 
We generated a scAAV9 vector packaging a construct consisting of 
Myc-tagged human MECP2 driven by the 229 bp Mecp2 promoter 
(MeP; Figure 5a) and tested this vector in male Mecp2 knockout 
mice. We have previously shown that IV administration of scAAV9 
vectors can lead to widespread and dose-responsive transduction 
of neurons and glia throughout the entire brain and spinal cord.25 
Four to five-week-old mice received scAAV9/MeP-MECP2 by 
tail vein infusion. Following injection, mice were weighed weekly 
and assessed for survival, with a 20% drop from their peak weight 
marking the endpoint for euthanasia and thus scored as a death. 
To assess the transduction efficiency in the brain, sections were co-
immunolabeled for NeuN and Myc-tagged MeCP2.
Figure 5b and Supplementary Figure S3 show that even when 
a relatively high dose of 5 × 1011 vector genomes (vg) was admin-
istered, a relatively small proportion of cells was transduced in the 
motor cortex (2.54 ± 1.04%), hippocampus (2.36 ± 1.08%), and stri-
atum (3.99 ± 1.77%) (n = 3 mice, >800 neurons counted per brain 
region across five sections per mouse; mean ± SEM). As expected 
from our previous studies on the tropism of AAV9 and the cell 
type specificity of the Mecp2 promoter,24,25 expression of MeCP2 
was predominantly neuronal (Supplementary Figure S3). Despite 
the low transduction efficiency, median survival was significantly 











































10 12 7 9












































AAV9/GFP + − + − + − + −
− + − + − + − +AAV9/MECP2
AAV9/GFP + − + − + − + −
− + − + − + − +AAV9/MECP2
AAV9/GFP + − + − + − + −

































































9 12 6 11
ns
9 12 6 11


























Figure 3 Improved motor but not respiratory phenotypes following 
neonatal delivery of MecP2. (a) Proportion of mice able to perform at 
two different speeds on a motorized treadmill. There was a significant 
overall difference in performance between groups (10 cm/second, P = 
0.0013; 25 cm/second, P < 0.0001; Fisher’s exact test). Post hoc pairwise 
comparison of AAV9/MECP2- and AAV9/GFP-treated mice showed a dif-
ference at 25 cm/second (P = 0.024), but not at 10 cm/second. (b–e) 
Open field tests performed at 9 weeks following AAV9 injection showing 
measures for (b) movement duration, (c) mean velocity, and (d) total 
distance moved (e) together with rearing frequency. (f) Representative 
whole-body plethysmograph traces showing regular and erratic breath-
ing patterns/apneas (arrows) in WT and Mecp2−/y mice, respectively. 
(g) Apnea frequency, (h) baseline breathing frequency, (i) breathing 
frequency variability. Both open field and respiratory measures were 
assessed by two-way ANOVA with Tukey’s post hoc comparisons. *P < 
0.05, **P < 0.01, ns = not significant. Number of animals per genotype/
treatment group are shown within each bar. AAV, adeno-associated virus; 
ANOVA, analysis of variance; CV, coefficient of variation; GFP, green fluo-
rescent protein; WT, wild-type.
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the untreated Mecp2-null mice used as controls (Figure 5c; n = 12 
scAAV9/MeP-MECP2–treated and n = 10 untreated mice; median 
survival was 15.4 and 10.6 weeks in these groups, respectively, 
P < 0.01, Gehan-Breslow-Wilcoxon test). There was no effect of 
scAAV9/MeP-MECP2 treatment on body weight (Supplementary 
Figure S4b). These results indicate that the MeP-MECP2 construct 
provides sufficient MeCP2 expression to prolong the lifespan of 
juvenile male Mecp2 knockout mice. There was a trend towards 
a dosage effect (Supplementary Figure S4a), with mice given the 
higher dose of scAAV9/MeP-MECP2 showing somewhat extended 
survival on average than those given the lower dose.
Given the low transduction efficiency in the brain following 
IV injection at 4–5 weeks and the corresponding modest thera-
peutic effects on survival, an improvement in the phenotype 
severity score was not investigated, but a cellular phenotype was 
investigated instead. MeCP2 is required for the maintenance of 
synaptic function in mature neurons, and activation of Mecp2 in 
the postnatal brain has been shown to reverse at least a subset 
of synaptic defects in Mecp2 knockout mice.6 Cell type-specific 
knockout of Mecp2 in γ-aminobutyric acid (GABA)ergic neu-
rons by Cre-mediated homologous recombination reduces cellu-
lar GABA content by nearly 40% in the adult mouse cortex and 
similarly reduces the amplitude of inhibitory synaptic currents.26 























































Figure 4 Increased nuclear volume in Mecp2−/y and wild-type 
mice after AAV9/cBA-MecP2 injection. (a,b) Representative image 
from the dentate gyrus of (a) wild-type and (b) Mecp2-null mouse at 
12 weeks following AAV9/MECP2 injection. Sections show DAPI-stained 
nuclei within the stratum granulosum and transfected cells identified by 
anti-Myc immunostaining (arrows). (c) Nuclear volume measurements 
from 3D-reconstructed DAPI-labeled nuclei in wild-type mice (n = 4). 
(d) Nuclear volume measurements from WT (n = 122 datapoints in total 
from four mice) non-transfected cells and transfected and non-transfected 
cells from age-matched Mecp2-null mice (n = 122 datapoints in total 
from from three mice). All data were normalized to the mean  volume in 
untransfected wild-type cells. Bar plots show mean ± SEM with gray dots 
showing individual datapoints. Statistical analysis was carried out by two-
way ANOVA and Tukey’s post hoc pairwise comparison. ***P < 0.001. Bar 
= 10 μm. AAV, adeno-associated virus; ANOVA, analysis of variance; DAPI, 
4′,6-diamidino-2-phenylindole; ns, not significant; WT, wild-type.
Figure 5 enhanced survival following intravenous delivery of scAAV9/
MeP-MecP2 virus to juvenile mice. (a) A MECP2_e1/Myc fusion con-
struct was cloned into a scAAV2 ITR backbone under a truncated ver-
sion of the murine Mecp2 promoter. (b) Graph showing transduction 
efficiency in three brain areas of Mecp2-null mice (n = 3) at endpoint fol-
lowing tail vein injection of scAAV9/MeP-MECP2. See Supplementary 
Figure S3 for representative images. Plots show mean ± SEM. (c) Survival 
plot showing extended survival of Mecp2−/y mice injected with scAAV9/
MeP-MEPC2 (purple open squares, n = 12) compared with untreated 
controls (green closed squares, n = 10). The median survival period in 
the treated mice was significantly higher than in the untreated group 
(15.4 versus 10.6 weeks, respectively, P < 0.01, Gehan-Breslow-Wilcoxon 
test). Control WT mice showed no mortality over the experimental period 
(closed circles, n = 8). Arrow indicates scAAV/MeP-MECP2 injection time. 
(d) Micrographs showing GABA immunolabeling of transduced (MeCP2-
positive, arrows) and non-transduced cells (arrowheads) in layer 2/3 of 
motor cortex of a Mecp2-null mouse. (e) Bar plot showing elevated levels 
of anti-GABA immunofluorescence in transduced cells (***P < 0.001, t-test, 
n = 166 cells). Bar in d = 10 μm. AAV, adeno-associated virus; BGHpolyA, 
bovine growth hormone polyadenylation signal; GABA, γ-aminobutyric 
acid; ITR, inverted terminal repeat; mut ITR, mutated inverted terminal 
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To determine whether postnatal scAAV9/MeP-MECP2–mediated 
MeCP2 expression is sufficient to rescue aspects of inhibitory 
neuron function in the Mecp2-null brain, we quantified GABA 
content in the soma of MeCP2-positive (transduced) and MeCP2-
negative GABAergic interneurons in layer 2/3 of motor cortex 
(Figure 5d,e). Mean GABA levels in exogenously derived MeCP2-
positive cells were 164.6 ± 9.3% of levels in MeCP2-negative cells 
in the same fields (Figure 5e; n = 124 MeCP2-negative neurons, 
42 MeCP2-positive neurons, P < 0.001).
After IV delivery AAV9-mediated transduction is 
widespread in peripheral organs
The low transduction efficiency of brain cells after IV delivery of 
the scAAV9 vectors that we have described above led us to inves-
tigate the distribution of the packaged transgene (i.e., the vec-
tor biodistribution) in the periphery to assess the potential for 
MeCP2 overexpression-related toxicity. It is known that following 
IV injection of AAV9, the vector preferentially targets peripheral 
organs, whereas in the CNS a considerably smaller transduction 
rate is usually observed.25,27
Juvenile WT mice (4–5 weeks old) were injected IV with 
vehicle, with 1 × 1011 vg scAAV9/MeP-GFP, or with 1 × 1011 vg 
scAAV9/MeP-MECP2, then killed after 1 or 3 weeks (i.e., at age 
5–6 weeks or 7–8 weeks). As expected, the AAV9 vector preferen-
tially targeted the liver and the spleen (Figure 6a), with between 1 
and 10 copies of the vector present per cell on average (assuming 
that most liver cells are still diploid at the ages employed here). 
Levels of vector in heart and kidney were approximately tenfold 
lower than this, and levels in the brain and spinal cord were nearly 
100-fold lower, consistent with the transduction rates in brain 
reported above. No obvious differences in vector DNA levels were 
observed between the MECP2 and GFP vectors, or between the 1- 
and 3-week time points, for any organ. Within the limits of experi-
mental sensitivity, no vector DNA signal could be detected in the 
vehicle-injected animals.
MECP2 expression levels were also assessed by reverse tran-
scription-quantitative PCR (RT-qPCR) in the same organs, using 
tissue from the same set of mice used for the biodistribution stud-
ies and expressing transcript abundance relative to that of actin 
transcripts in the same tissues (Figure 6b). We ascertained on the 
basis of a melting curve analysis of the PCR products (see Materials 
and Methods and Supplementary Table S1) that for the +MECP2 
mice, in the organs with the highest vector biodistribution we could 
detect AAV9 vector-derived human MECP2 expression whereas 
only the endogenous mouse Mecp2 expression was detected in 
the GFP and vehicle-treated mice. At 3 weeks post-injection, rela-
tive levels of endogenous Mecp2 transcripts (ascertained from the 
vehicle-injected mice) were comparable with those observed pre-
viously at a comparable time point10 except for spleen, in which 
transcript abundance was unexpectedly low. Although sample 
sizes prohibited detailed statistical analysis, we also observed that 
there was a trend towards increasing Mecp2 expression levels in 
all organs between the 1-week post-injection time point (i.e., 5–6 
weeks of age) and the 3-week post-injection time point (i.e., 7–8 
weeks of age), based on data from the  vehicle-injected mice; such 
age-related changes have been reported before.28 This pattern of 
transcript abundance change was also observed in the +MECP2 
mice, and for kidney, brain, and spinal cord, transcript levels were 
approximately the same as those in the vehicle-injected mice, con-
sistent with the vector load (Figure 6a). In the liver and heart, 
however, the transcript abundance was much higher at week 3 in 
the +MECP2 mice compared with the vehicle-injected mice, sug-
gesting that the high vector load in these organs (Figure 6a) led to 
high levels of human MECP2 expression in addition to the endog-
enous mouse transcript. The high vector DNA load in the spleen 
and the lack of additional MECP2 transcript in the +MECP2 
mice are consistent with previous reports that the MeP promoter 
confers poor transgene expression in the spleen after IV AAV9-
mediated transduction.24
Where vector load is high and exogenous MECP2 is expressed 
at high levels from an efficient promoter, overexpression toxicity 
is a potential concern. We assessed a number of serum markers of 
organ dysfunction in the mice used for the biodistribution analy-
sis (Supplementary Figure S5). There was no significant differ-
ence in the levels of these markers between the AAV9/GFP-treated 
and vehicle-injected mice. The difference between AAV9/MECP2-
treated and vehicle-injected mice was, however, quite marked 
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1 week (+GFP )
1 week (+vehicle)
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Figure 6 Vector biodistribution and gene expression after intra-
venous injection. WT C57BL/6 mice were injected intravenously at 
4–5 weeks old with vehicle, 1 × 1011 vg scAAV/MeP-GFP (+GFP), or 
1 × 1011 vg scAAV/MeP-MECP2 (+MECP2), then killed at 1 or 3 weeks 
post- injection. (a) qPCR biodistribution of GFP or MECP2 vector genomes 
to major organs. (b) RT-qPCR of total MECP2 (mouse + human) relative 
to actin. Mean ± SEM are plotted, n = 2–4, with the exception of the 
+GFP mice at 3 weeks (n = 1). #Not determined. AAV, adeno-associated 
virus; GFP, green fluorescent protein; RT-qPCR, reverse transcription-
quantitative PCR; vg, vector genome; WT, wild-type.
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liver damage, with increased levels observed in the AAV9/MECP2-
treated mice. This may indicate that the high vector load and effi-
cient transcription of MECP2 in liver cells has led to some liver 
dysfunction in the treated mice.
dIscussIon
expression of MecP2 as a result of AAV-mediated 
gene delivery to the Mecp2 knockout mouse 
cns confers a survival benefit and phenotypic 
improvement
Incomplete understanding of the precise molecular actions of 
MeCP2 continues to impede the development of rational thera-
peutic strategies for RTT. In theory, delivery of a WT copy of 
the MECP2 gene to cells lacking functional MeCP2 represents a 
therapeutic approach worth considering. In this study, we provide 
evidence at the proof-of-concept level that exogenous delivery 
of the human MECP2 gene to the CNS of Mecp2-null male mice 
can result in levels of MeCP2 expression that lead to a reduction 
in phenotypic severity. We show that early postnatal delivery of 
exogenous MECP2 directly to the brain at transduction efficien-
cies in the range of ~7–42%, depending on brain region, results in 
a substantial prolongation of lifespan (~80% increase in median 
survival) and a less aggressive trajectory of RTT-like phenotype 
severity (Figure 2). Interestingly, a small number of treated mice 
survived to the end of the 37-week study period, well in excess 
of the median lifespan of the control Mecp2-null mice (lifespan 
was greater than threefold greater for some AAV9/CBA-MECP2–
treated mice). Furthermore, the longest-lived mice treated with 
the therapeutic vector also displayed a stabilization of the pheno-
type in terms of aggregate severity score and objective locomo-
tor measures. Male mice lacking MeCP2 in all cells display the 
most severe phenotype observable in any mouse model of RTT 
and thus provide an especially challenging system for assessing 
the potential of novel therapeutic approaches. Nevertheless, these 
data show that treatment with the AAV9/CBA-MECP2 vector 
can influence phenotype progression and lifespan. In contrast 
to the observed beneficial impact on the RTT-like signs, AAV9/
CBA-MECP2 treatment resulted in only a modest, nonsignifi-
cant increase in body weight of Mecp2-null mice compared with 
 control-treated Mecp2-null mice, even for the most long-lived ani-
mals. Among several potential reasons for this observation are the 
possibility that exogenously derived MeCP2 expression levels in 
relevant areas of the brain did not reach a threshold for affecting 
body weight or that reduced body weight in Mecp2-null mice is at 
least in part due to MeCP2 deficiency in peripheral organs rather 
than solely the brain. However, the relationship between animal 
“health” and body weight is not straightforward, with other stud-
ies also showing little change in body weight despite a dramatic 
arrest of phenotype and prolongation of lifespan.29
The effect of the AAV9/MECP2 treatment on the motor/
locomotory phenotype of the Mecp2-null mice was especially 
notable and robust–treatment led to substantial improvements in 
both open field activity/locomotion and performance in a forced 
motor task. The impaired locomotor activity observed in the 
control vector-treated Mecp2-null mice in the open field experi-
ments can be explained by genuine motor disability, by an anxiety 
phenotype or by a lack of motivation. The complete inability of 
AAV9/GFP-treated mice to perform in a forced motor challenge 
when tested at the high speed on the treadmill and their partial 
ability to perform at low speed suggest the presence of a genuine 
motor defect rather than inertia purely due to lack of motivation. 
This motor impairment was ameliorated by AAV9/CBA-MECP2 
treatment, and the effect was mirrored in the open field test, in 
which the AAV9/CBA-MECP2–treated mice displayed signifi-
cantly enhanced ambulatory activity. Locomotor improvement 
was accompanied by an increase in rearing frequency in AAV9/
CBA-MECP2–treated mice, suggesting additional improvement in 
exploration-related behavior. Analysis of longitudinally collected 
open field data from the long-term survivors suggests that the loco-
motor phenotypes are not progressive throughout life in AAV9/
CBA-MECP2–treated null mice (Supplementary Figure S2b–d). 
Reports by other groups as to whether anxiety phenotypes that 
can be measured by open field test are visible in young Mecp2-null 
mice have not revealed consistent observations.12,30,31 We found no 
genotype or treatment differences in the proportion of time spent 
in the central zone of the open field (data not shown) and there-
fore did not investigate this further.
The analysis of breathing was consistent with other reports 
that Mecp2-null mice exhibit a range of breathing phenotypes,32 
mirroring the clinical picture where apneas and other breathing 
irregularities are characteristic and highly prevalent features of 
RTT.1 Previous studies have shown that postnatal activation of 
Mecp2 globally33 or in glial cells12 can rescue abnormal breathing 
and this suggests that the respiratory phenotype is not solely the 
result of an earlier developmental deficit and is amenable to treat-
ment at the level of causative gene function. The absence of any 
impact of AAV9/CBA-MECP2-treatment on breathing irregular-
ity or on the incidence of apneas in the mutant mice in this study 
could be explained if, despite the widespread expression of exog-
enous MeCP2, the cells responsible for breathing rhythmogenesis 
or otherwise contributing to breathing regulation were transduced 
at levels below a threshold for improved functioning.
MeCP2 deficiency is known to be associated with a wide vari-
ety of morphological and neurochemical changes in the brain.2 
To examine the consequences of exogenous MECP2 delivery, sim-
ple measures of cellular phenotype, including neuronal nuclear 
volumes within the dentate gyrus (CBA-MECP2 construct) and 
the GABA content of GABAergic interneurons within the cortex 
(MeP-MECP2 construct), were investigated. The significant reduc-
tion in neuronal nuclear volume in MeCP2-deficient cells has been 
reported previously5,23 and our results show that this cell morpho-
logical measure can be effectively rendered normal by the expres-
sion of exogenously derived MeCP2 at close to WT levels within 
the nucleus. Furthermore, the comparison between neighboring 
MeCP2-containing and MeCP2-deficient cells within individual 
brains suggests that these changes represent a cell autonomous 
effect. This would be consistent with differences that we have 
observed in nuclear volume and soma size between neurons con-
taining MeCP2 and those lacking MeCP2 in the heterozygous 
female (Mecp2+/−) mouse brain34 (K. Gadalla, S. Cobb, unpub-
lished observations). The fact that nuclear volume becomes nor-
mal after expression of exogenously derived MeCP2 suggests that 
the appearance of MeCP2 in a previously MeCP2-negative neuron 
leads to structural remodeling within the nucleus. Whether this 
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remodeling also extends to changes in dendritic/axonal size and 
complexity, as shown in response to exogenously derived MeCP2 
in neuronal culture35 and upon delayed activation of Mecp2 in 
mature brains,33 remains to be established.
The increases we observed in GABA content in cortical 
GABAergic interneurons upon MeCP2 re-expression in juvenile 
mice suggest one possible mechanism through which AAV-based 
gene therapy could lead to recovery of neuronal circuit function. 
A previous study has shown that cell type-specific deletion of 
Mecp2 in GABAergic neurons reduces GABA content (~40% in 
cortical interneurons) and leads to a variety of RTT-like pheno-
types including motor deficits.26 Our finding that exogenous deliv-
ery of MeCP2 elevates/restores GABA levels raises the possibility 
that improved GABAergic synaptic function in the scAAV9/MeP-
MECP2–treated mice accounts at least in part for their milder 
motor phenotypes compared with control null mice.
Potentially serious complications have been attributed to MeCP2 
overexpression.7,21,36 The present studies demonstrate the potential 
for achieving expression of exogenously derived MeCP2 without 
overt overexpression-related toxicity within the CNS, at least with 
the vector designs utilized in this study and with the delivery efficien-
cies achieved. That said, in early pilot experiments (data not shown) 
we observed that introducing MeCP2 intracranially using scAAV9/
MeP-MECP2 in neonatal mice achieved very high transduction 
efficiency and high levels of cellular expression, which resulted in 
a delayed onset overexpression-related toxicity with similarities to 
that reported previously.7 Moreover, we observed elevated levels of 
a liver damage marker (alanine aminotransferase) after peripheral 
delivery of the scAAV9/MECP2 vector to juvenile mice. Expression 
levels in these mice were consistent with a high vector load in the 
liver. These results suggest that the expression cassette provides a 
tolerable level of expression from one copy of the vector per cell, but 
overloading a particular cell with many copies of vector may lead to 
a deleterious overexpression phenotype. The lack of any phenotypic 
deficits in WT mice injected as neonates with the ssAAV9/CBA-
MECP2 vector, however, which had approximately double normal 
levels of MeCP2 in transduced brain cells, suggests that in situations 
where vector load is modest (≤1 vector being present within each 
cell), this level of MeCP2 overexpression is tolerated. We cannot, of 
course, rule out the possibility of subtle or very delayed overexpres-
sion toxicity under these conditions,37 but the same dose in male 
Mecp2-null mice (conferring cellular MeCP2 levels in null cells that 
were one to 1.25-fold higher than levels in WT cells) provided a 
significant behavior and survival benefit. Moreover, none of the 
4–5 weeks old male Mecp2-null mice in this study injected with the 
scAAV9/MeP-MECP2 vector showed the mortality associated with 
up to 50% of mice upon rapid genetic reactivation of an inactive 
Mecp2 allele in 6-week-old male Mecp2-mutant mice.6 The implica-
tions of these findings are particularly important when we consider 
this approach for RTT females (who have a mosaic pattern of cells 
expressing either the normal or mutant MECP2 allele). Here, there 
is a concern that overexpression toxicity might result from introduc-
tion of MeCP2 to cells expressing the endogenous WT allele while 
trying to achieve therapeutic levels of MeCP2 in the cells expressing 
the mutant allele. Our data shows that it may be possible to achieve 
a therapeutic outcome without the associated overexpression toxic-
ity using an appropriate vector and promoter system.
Vector design and translational implications
In the current study, delivery of MECP2 was initially conducted 
at an early postnatal age (P0-2) in order to achieve high neuronal 
transduction efficiency14,38,39 and to test the effect of early introduc-
tion of exogenously derived MeCP2 on the trajectory of the RTT-
like phenotype. The clear influence that ssAAV9/CBA-MECP2 had 
on survival and motor phenotypes in this study contrasts with the 
failure of a similar vector to impact the survival of male Mecp2-
null mice when injected IV at 4–8 weeks of age.12 One interpreta-
tion of this difference is that later postnatal delivery of MECP2 
might be ineffective in affording phenotypic benefit. However, 
in our study, delivery of MECP2 at an equivalent later time point 
using a sc vector (Figure 5c) had a significant survival benefit, 
while reactivation studies by other groups in which Mecp2 silenc-
ing is reversed at late time points6,33 also suggest that the latency of 
MeCP2 restoration is not a critical issue. More important factors 
are likely to be the level of MeCP2 within each cell as well as the 
proportion of cells transduced. Indeed, reactivation studies have 
demonstrated a relationship between numbers of cells re-express-
ing MeCP2 and the degree of phenotypic rescue.33
The increased transduction efficiency that comes from the use 
of scAAV vectors18,19,25 is likely to be critical to the success of a 
translationally relevant RTT gene therapy. The novel scAAV vec-
tor design we describe, in which MeCP2 expression is driven by 
a fragment of the Mecp2 promoter, was able to provide a modest 
survival benefit to Mecp2-null mice. However, the low transduc-
tion efficiency of neurons (2–4%) given the peripheral adminis-
tration route, coupled with this modest therapeutic effect, suggest 
that CNS delivery efficiency remains the major factor limiting fur-
ther efficacy with this approach. The high level of MeCP2 expres-
sion in the liver and associated evidence for liver damage after 
intravascular delivery of the vector suggest that a high concentra-
tion of vector in any particular cell population is something to be 
avoided. In formulating translational strategies, this is likely to be a 
critical issue. Any viable solution will require widespread distribu-
tion of vector across the CNS but minimal concentration of vector 
in peripheral tissues that are sensitive to MeCP2 overexpression. 
Whether the required distribution is more likely to come from 
direct brain injection, peripheral intravascular injection or injec-
tion into the cerebrospinal fluid25,40–42 remains to be explored.
A further issue relates to whether we have reached a full under-
standing of the complement of cell types that underlie the RTT 
disease phenotype and the extent to which we have yet to explore 
which cell types, when rendered fully functional, will have the larg-
est influence on amelioration of the phenotype after treatment. A 
recent report by Derecki and colleagues29 demonstrated a robust 
arrest of the RTT-like phenotype after transplantation of WT micro-
glial precursors from bone marrow into juvenile Mecp2-null mice. 
Application of this approach in patients is not straightforward, as it 
may involve first ablating the resident MeCP2-deficient population 
of microglia in the brain. If microglia do prove to be the cell type 
with the largest influence on the phenotype when corrective treat-
ments are used, then a gene therapy approach in which microglia are 
targeted in preference to other cell types12 could be used to circum-
vent this problem. The promoters used in our current study were 
not geared to achieving preferential expression in nonneuronal cells 
and this approach necessitates development of a new generation of 
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appropriate vector constructs. Alternatively, however, we can envis-
age a future strategy in which vectors targeting microglial precur-
sors in the periphery could be employed. Fixing both the genotype 
and phenotype of such cells could be successful if population of 
the brain by these peripheral precursors could be achieved. As an 
alternative, given the findings implicating various cell autonomous 
defects in neurons lacking MeCP2, it is possible that a strategy 
involving both microglial cell transplantation and targeted delivery 
of MECP2 to neurons using viral vectors might be worth investigat-
ing for its potential to produce a synergistic outcome.
While encouraging, the results of our study demonstrate only 
the first step in the development of a RTT gene therapy approach 
suitable for human translation. The results suggest that a more 
efficient and CNS-specific delivery system appropriate for the 
human scale is needed for RTT gene therapy. Alternative routes of 
administration and improvements in vector design offer possible 
solutions to this problem.40–42
concluding remarks
This work shows, at “proof-of-concept” level, that exogenous MeCP2 
can be delivered at a physiologically tolerable level via AAV2/9 vec-
tors to the brain of Mecp2-null mice. Three main issues affecting the 
development of RTT gene therapy approaches have been addressed 
in this study. First, we have shown that partial amelioration of the 
RTT-like phenotype in the null mouse model can be achieved via 
provision of exogenously derived MeCP2. Second, we have shown 
that MeCP2 can be expressed at levels that are both efficacious in 
the null mouse and tolerated in WT mice, providing a broader-
than-anticipated window of therapeutic MeCP2 expression. Third, 
we have identified CNS delivery efficiency and overexpression 
in peripheral organs as limiting factors for any future translation 
approaches. Longer-term studies in heterozygous female mice, 
along with development of more sensitive mouse phenotyping tools 
and improvements in global CNS gene delivery are the next steps 
before any human application can be considered.
MAterIAls And Methods
Animals. All investigations in Glasgow were carried out in accordance with 
the European Communities Council Directive (86/609/EEC) and with the 
terms of a project licence under the UK Scientific Procedures Act (1986). 
All experiments in North Carolina were approved by the University of 
North Carolina–Chapel Hill (UNC) Institutional Animal Care and Use 
Committee. The Mecp2-null mice (B6.129P2(C)-Mecp2tm1.1Bird/J) used at 
UNC (treated at 4–5 weeks of age) were obtained from Jackson Laboratory 
(Bar Harbor, ME). The studies at University of Glasgow (using mice that 
were treated as neonates) used Mecp2tm1.1Bird mice which were originally 
provided as a kind gift from Professor Adrian Bird and maintained on a 
C57BL/6/CBA mixed background. Animals were maintained on 12-hour 
light/dark cycles with free access to normal mouse food. Mice were geno-
typed as described previously.3
Virus preparation. Recombinant AAV vector particles were generated 
using HEK293 cells grown in serum-free suspension conditions in shaker 
flasks, using proprietary methods developed at the UNC Gene Therapy 
Center Vector Core facility. In brief, ssAAV or scAAV particles (AAV2 
ITR-flanked genomes packaged into AAV9 serotype capsids) were pro-
duced from suspension HEK293 cells (no. CRL 1573; ATCC, Manassas, 
VA) transfected using polyethyleneimine (Polysciences, Warrington, PA) 
with the following helper plasmids (pXX6-80,43 pGSK2/9) plus one of 
three inverted terminal repeat-flanked transgene constructs (pTR-CBA-
GFP, pTR-CBA-hMeCP2, pSJG-MeP229-hMeCP2, or pSJG-MeP229-GFP, 
respectively) to generate each respective ssAAV or scAAV vector. The CBA 
constructs utilized a cytomegalovirus enhancer, modified CBA promoter, 
shortened SV40 intron, and SV40 polyadenylation sequence.44 The MeP 
constructs used a truncated 229 bp murine Mecp2 promoter,44 along with 
the bovine growth hormone polyadenylation signal following MeCP2 or 
the SV40 polyadenylation signal for GFP.24 All MeCP2-expressing con-
structs utilized the human MECP2 coding region (MECP2_e1 mRNA 
isoform) with a C-terminal Myc epitope tag. Forty-eight hours post-trans-
fection, cell cultures were centrifuged and supernatant discarded. The cells 
were resuspended and lysed by sonication, as described.45 DNase (550 U) 
was added to the lysate and incubated at 37 °C for 45 minutes, followed by 
centrifugation at 9,400g to pellet the cell debris and the clarified lysate was 
loaded onto a modified discontinuous iodixanol gradient followed by col-
umn chromatography, or purified by a step CsCl gradient centrifugation 
followed by a discontinuous CsCl gradient centrifugation. Both purifica-
tion methods provide equivalent high levels of purity and in vivo transduc-
tion efficiency.46 Purified vectors were dialyzed in 1× phosphate-buffered 
saline (PBS) with 5% D-sorbitol and a final NaCl concentration of 350 
mmol/l. AAV titer was obtained by both dot blot45 and qPCR.25
Injection and phenotyping. For the studies employing AAV delivery neo-
natally, male littermates were sexed at birth and at P0-3 received, unanes-
thetized, direct bilateral injections of virus (3 µl per site; 8 × 1012 vg/ml 
titer; i.e., 4.8 × 1010 vg/mouse) into the neuropil (Figure 1b) via a 33 g 
needle/10 µl Hamilton syringe over a 10–20 seconds period. The needle 
was then removed slowly after a delay of 30–60 seconds. The injection 
sites were over the temporal cortex, ~1–2 mm lateral from the midline and 
~2 mm anterior to lambda and at an approximate depth of 2–4 mm.47
The injected pups were returned to the home cage containing their 
uninjected littermates. Genotyping was carried out at 3 weeks, at which 
time phenotyping also commenced. Mice were observed and scored (blind 
to genotype and treatment) on a weekly basis according to an established 
phenotype scoring system.6
Open field test. Motor function and anxiety were evaluated at 9–11 weeks 
of age using the well-established open field test. Mice were placed in 
the center of a 60 cm diameter arena and allowed to ambulate freely for 
40 minutes during which time the experimenter left the room. The arena 
was filmed using an overhead digital camera and the digital tracks for each 
mouse were analyzed for various motor and anxiety parameters using 
Ethovision 3.1 tracking software (Noldus, Leesburg, VA).
Whole-body plethysmograph. Respiratory phenotype was determined at 
9–11 weeks of age in conscious and unrestrained animals using whole-
body plethysmography (EMMS, Bordon, UK). Animals were placed inside 
a plexiglass chamber for 20 minutes to become adapted to the environ-
ment after which their breathing was monitored for 30 minutes. A con-
tinuous bias airflow supply allowed the animal to be kept in the chamber 
for extended periods of time. Pressure changes caused by alterations in the 
temperature and humidity of the air as it enters and leaves the subjects’ 
lungs were detected by a pressure transducer and signals amplified and con-
verted to a digital display using the custom software (EMMS) to produce a 
waveform representing the breathing pattern of the animal. This waveform 
was then exported and analyzed using pClamp 10.2 (Molecular Devices, 
Sunnyvale, CA). Pressure changes were calibrated by injecting 1 ml of air 
via syringe. Respiratory waveforms were analyzed for frequency, frequency 
variability, and the presence of abnormal breaths and apneas (expiratory 
pauses lasting >3 times the mean breath length for that animal).33
Treadmill motor challenge test. A treadmill challenge test was carried 
out using the DigiGait imaging system (Mouse Specifics, Boston, MA) as 
described.48 Digital videos were captured as mice ran at varying speeds 
(10 and 25 cm/second) on a transparent treadmill. Mice were contained 
within a plexiglass chamber, with front and rear bumpers, that was placed 
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on top of the treadmill to ensure the animals remained visible to the cam-
era at all times. A run was considered as successful if the animals could run 
at the set speed for 10 consecutive steps (~2 seconds) without sliding back 
and hitting the rear bumper with their hindquarters.
AAV injection experiments using juvenile mice. To investigate the effects 
of juvenile delivery of scAAV9/MeP-MECP2, 100 μl of vector of the indi-
cated titers (either low dose: 1 × 1011 vg; or high dose: 5 × 1011 vg) were 
injected into the tail vein of 4–5 weeks old male Mecp2-null mice. Mice 
were weighed at the time of injection and weekly thereafter. Mice were 
euthanized as the study endpoint when their body weight decreased to 
80% of its peak level.
Vector biodistribution analysis utilized tail vein injections (100 µl, as 
above) into 4–5 weeks old WT C57BL/6 mice. Mice were injected with 
vehicle (350 mmol/l PBS containing 5% sorbitol), 1 × 1011 vg scAAV9/
MeP-MECP2, or 1 × 1011 vg of scAAV9/MeP-GFP. Mice were killed after 1 
or 3 weeks. At killing, blood was collected transcardially and the following 
organs were harvested for DNA and RNA purification: brain, lumbar 
spinal cord, liver, heart, spleen, and kidney. A portion of the liver was 
retained for immunohistochemical detection of GFP or MeCP2.
Immunohistochemistry. To validate the expression of exogenously derived 
MeCP2 in mice injected neonatally, mice were deeply anesthetized with 
pentobarbitone (50 mg, intraperitoneally) and transcardially perfused 
with 4% paraformaldehyde (0.1 mol/l PBS). A vibrating microtome (Leica 
VT1200; Leica, Milton Keynes, UK) was used to obtain 50 µm sections of 
brain, spinal cord, and a variety of different peripheral organs. Sections were 
washed three times in 0.3 mol/l PBS followed by blocking using 15% normal 
goat serum in 0.3 mol/l PBS with 0.3% Triton X-100 for 1 hour at room 
temperature. Samples then were incubated for 48 hours on a shaker at 4 °C 
with the following primary antibodies: rabbit anti-Myc (Abcam product 
code ab9106, 1/500 dilution; Abcam, Cambridge, MA); mouse anti-NeuN 
(Millipore, Billerica, MA; 1/500), mouse anti-MeCP2 (Sigma, St Louis, MO; 
1/500). The primary antibodies were then washed off (3 × 0.3 mol/l PBS) 
and secondary antibodies applied to the sections overnight at 4 °C: Alexa 
fluor 488 goat anti-mouse/rabbit (Invitrogen, Carlsbad, CA; 1/500) and 
Alexa fluor 546 goat anti-mouse/rabbit (Invitrogen; 1/500). Finally, sections 
were incubated with 4′,6-diamidino-2-phenylindole (DAPI) nuclear stain 
(Sigma, Poole, UK; 1/1,000) for 30 minutes at room temperature before 
mounting with Vectashield (Vector labs, Peterborough, UK).
For immunofluorescence studies of mice injected at 4–5 weeks old, 
mice were transcardially perfused with PBS, then after 48 hours of fixation 
in freshly made PBS containing 4% paraformaldehyde, the entire brain and 
liver were sectioned at 40 µm using a Leica vibrating microtome. Sections 
were incubated for 1 hour at room temperature in blocking solution (10% 
goat serum, 0.1% Triton X-100, 1× PBS), then incubated 48–72 hours at 
4 °C in primary antibody solution (3% goat serum, 0.1% Triton X-100, 
1× PBS, rabbit anti-Myc (Abcam ab9106; 1:500) alone, rabbit anti-Myc 
plus mouse anti-NeuN (Millipore; 1:500), or mouse anti-MeCP2 (Abcam, 
1:1,000) plus rabbit anti-GABA (Sigma 1:100)). After washing three times 
with PBS, the sections were incubated for 1 hour at room temperature 
in secondary antibody solution (3% goat serum, 0.1% Triton X-100, 
1× PBS, secondary antibodies), then washed three more times in PBS. 
Secondary antibodies were as appropriate, each at 1:1,000 dilution: goat 
anti-rabbit Alexa 488 (Invitrogen no. A11008), goat anti-mouse Alexa 594 
(Invitrogen no. A11032).
Image analysis. Analysis of expression patterns, transduction efficiency, 
and quantification of exogenously derived MeCP2 levels within nuclei 
was carried out on image stacks captured using a Zeiss LSM710 or Zeiss 
Axiovert LSM510 laser confocal microscope (Zeiss, Cambridge, UK). 
Z-series were taken at 0.6–1.3 μm intervals through the section of interest 
using a ×20 objective.
To estimate transduction efficiency in neonatally injected mice, 
images were captured as above and the ratio of Myc-immunopositive 
nuclei to DAPI-stained nuclei was calculated for random fields (n = 18 
from four mice) from sections of hippocampus (CA3), layer 5 of primary 
motor cortex, thalamus, hypothalamus, brainstem, and striatum. For 
mice injected as juveniles, hippocampus, motor cortex, and striatum were 
analyzed similarly. To assess the percentage of transduced cells that were 
neurons, the ratio of NeuN-immunopositive cells to Myc-immunopositive 
cells was determined. To quantify levels of exogenously derived MeCP2 
per nucleus in WT mice, injections of ssAAV9/CBA-MECP2 were carried 
out at P0-2 and brains perfused at 12 weeks. Sections were stained with 
anti-Myc and anti-MeCP2 and confocal stacks obtained as above. ImageJ 
software (http://rsbweb.nih.gov/ij/) was used to determine mean MeCP2-
channel fluorescence intensity within transduced (Myc +ve) and non-
transduced (Myc −ve) cells within a 15 μm image stack.
Nuclear volume estimation was conducted by serial reconstruction 
of nuclei in a Z-series (0.6 μm) using ImageJ. Fluorescence in the DAPI 
channel was used to define the nuclear boundary and thus to calculate 
nuclear volumes, whereas the transduction status of cells was ascertained 
by the presence or absence of anti-Myc labeling in another channel.
For quantitative immunofluorescence of GABA immunoreactivity, 
we captured images of neurons in layer 2/3 of motor cortex that had been 
double-stained with antibodies against MeCP2 and GABA. Fields containing 
MeCP2-expressing cells were identified, and cellular colocalization of 
MeCP2 expression and GABA subsequently evaluated. Images of these cells 
were captured with a ×40 oil lens on a Leica DMI4000 inverted fluorescence 
microscope using a Cascade 512B camera and digital images were analyzed 
using MetaMorph 7.0 Image Analysis software (Molecular Devices), using 
the “count nuclei” module to evaluate the integrated intensity of the GABA 
immunoreactivity in the sentinel MeCP2-expressing neuron. GABA content 
was then quantified in the three closest Mecp2-null GABA-expressing 
neurons in the same field of view.
scAAV vector biodistribution and MECP2 transcript quantification. 
Genomic DNA was recovered from tissues using the DNeasy Blood and 
Tissue kit (Qiagen, Valencia, CA), with automated purifications done on 
a Qiacube (Qiagen). RNA was recovered from tissues using the RNA Mini 
Plus kit (Qiagen), tissue lysis performed with the TissueLyser (Qiagen), 
and automated purification carried out on a Qiacube (Qiagen). cDNA was 
synthesized from the purified RNA using the Transcriptor First Strand 
cDNA Synthesis kit (Roche, Indianapolis, IN), following the manufacturer’s 
instructions, then used directly as template for RT-qPCR. Genomic qPCR 
and RT-qPCR reactions and analysis were carried out on a Roche Lightcycler 
480, following the manufacturer’s instructions and as described.49
For the quantification of vector biodistribution, the amount of vector 
genome present in each sample was standardized against an amplicon 
from a single copy mouse gene, laminB2, amplified from genomic DNA. 
For the quantification of GFP, mouse Mecp2, and human MECP2 cDNAs, 
standardization was achieved by comparison against standard curves 
generated by amplification from plasmid constructs specific for each of 
these transcripts. This enabled estimation of absolute numbers of transcripts 
in each sample, and absolute numbers of a reference housekeeping gene 
transcript, actin, were estimated using a standard curve generated by 
amplification from mouse genomic DNA. Vector biodistribution data is 
reported as the number of double-stranded vector DNA (GFP or human 
MECP2) molecules per two copies of the mouse LaminB2 locus, i.e., the 
number of vector DNA copies per diploid mouse genome. Transcript 
quantification is reported as the absolute number of human MECP2 + 
mouse Mecp2 transcripts/µl (using “universal” primers that amplify both 
human and mouse transcripts with equal efficiency) divided by the absolute 
number of actin transcripts/µl in the sample. Primers for human MECP2 
were as follows: forward: 5′-caccacgagacccaaggcggcca-3′; reverse: 5′-
ggtctcctgcacagatcggata-3′. Universal MECP2/Mecp2 primers were as follows: 
forward: 5′-ccggggacctatgtatgatg-3′; reverse: 5′-aagcttttccctggggatt-3′. 
Primers for mouse actin were as follows: forward: 5′-tggcaccacaccttctacaat-3′; 
reverse: 5′-aggcatacagggacagcaca-3′. Primers for GFP and LaminB2 were as 
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described.49 A melting curve analysis was performed at the end of the RT-
qPCR run, following the manufacturer’s instructions, to distinguish and 
quantify the mouse Mecp2 and human MECP2 transcript amplification 
products. The mouse product melted at 81.9 °C and the human melted at 
83.5 °C. Only the MECP2-treated mice showed evidence for human MECP2 
expression (Supplementary Table S1).
Serum chemistry. Blood recovered from mice was allowed to clot for 2 
hours at room temperature, and was then centrifuged at 1,000g for 10 min-
utes. The clear upper phase (serum) was collected and preserved at −80 °C. 
Serum analysis was conducted by the University of North Carolina Animal 
Clinical Laboratory Core Facility.
Statistical analysis. Differences between treatment groups were carried 
out using two-way ANOVA, repeated-measures ANOVA, Fisher’s exact 
test, Student’s t-test, and Gehan-Breslow-Wilcoxon test (survival curves), 
as appropriate. P < 0.05 was used to define statistical significance.
suPPleMentArY MAterIAl
Figure S1. AAV9/CBA-MECP2 intracranial injection led to widespread 
brain, spinal cord, and liver retrograde transduction.
Figure S2. Phenotypic analysis of ssAAV9/CBA-MECP2–treated long-
lived mice.
Figure S3. Analysis of brain transduction efficiency in scAAV9/MeP-
MECP2–treated mice.
Figure S4. scAAV9/MeP-MECP2 treatment survival and body weight 
graphs.
Figure S5. Serum chemistry in WT mice injected IV with scAAV9/
MeP-MECP2.
Table S1. Melting curve analysis of RT-qPCR PCR products (product 
melting temperatures reported).
Video S1. Representative video showing AAV9/CBA-GFP treated 
MECP2−/y mouse at 7 weeks.
Video S2. Representative video showing AAV9/CBA-MECP2 treated 
MECP2−/y mouse at 7 weeks.
Video S3. Representative video showing AAV9/CBA-MECP2 treated 
MECP2−/y mouse at 16 weeks.
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